Table 1 Baseline characteristics of the participants in different vaccination regimen group
|  | Single-dose group | Two-dose group (the 0–1-month schedule) | Two-dose group (the 0–6-month schedule) | Three-dose group | Placebo group |
|---|---|---|---|---|---|
Sex, n (%) | 88 | 184 | 189 | 5567 | 6054 |
 Male | 47a (53.41) | 89a (48.37) | 88 (46.56) | 2171 (39.00) | 2427 (40.09) |
 Female | 41a (46.59) | 95a (51.63) | 101 (53.44) | 3396 (61.00) | 3627 (59.91) |
Age, median (IQR) | 46.0 (40.0–52.0) | 44.0a (37.0–51.0) | 45.0 (40.0–54.0) | 45.0 (38.0–53.0) | 45.0 (38.0–53.0) |
Baseline anti-HEV status, n (%) | |||||
 Anfeng | 68 | 152 | 159 | 4457 | 4855 |
 Seropositive | 28 (41.18) | 62 (40.79) | 73 (45.91) | 1989 (44.63) | 2123 (43.73) |
 Seronegative | 40 (58.82) | 90 (59.21) | 86 (54.09) | 2468 (55.37) | 2732 (56.27) |
Qindong | 20 | 32 | 30 | 1110 | 1199 |
 Seropositive | 10 (50.00) | 17 (53.13) | 19 (63.33) | 670 (60.36) | 710 (59.22) |
 Seronegative | 10 (50.00) | 15 (46.88) | 11 (36.67) | 440 (39.64) | 489 (40.78) |
